Search
fidanacogene elaparvovec-dzkt (Beqvez)
Indications:
- adenovirus-associated vector-based gene therapy indicated for treatment of adults with moderate to severe hemophilia B
Dosage:
- 5 × 1011 vector genomes per kg
- IV infusion after dilution in 0.9%sodium chloride with 0.25% human serum albumin, final volume of 200 mL over ~60 minutes
Adverse effects:
- hepatotoxicty
- hepatocellular carcinoma?
- increased serum transaminases
General
gene therapy
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
fidanacogene elaparvovec-dzkt (Beqvez) for intravenous infusion
https://labeling.pfizer.com/ShowLabeling.aspx?id=20452&format=pdf